277 surgeries performed due to faulty J&J hip implants: Minister

He said the government had set up a panel to examine issues relating to the faulty hip implants

Johnson & Johnson
A Johnson & Johnson building is shown in Irvine, California, US
Press Trust of India New Delhi
Last Updated : Dec 13 2018 | 12:30 AM IST

A total of 277 revision surgeries have been performed due to the faulty ASR hip implants manufactured by DePuy International Ltd, a subsidiary of Johnson and Johnson, Minister of State for Health Ashwini Choubey told the Rajya Sabha Tuesday.

The minister was replying to a question on whether faulty hip implants had resulted in deaths and disability of several patients.

"As per the information available with the Central Drugs Standard Control Organisation (CDSCO), 277 revision surgeries were undertaken because of disability due to faulty Articular Surface Replacement (ASR) hip implants manufactured by M/s DePuy International Limited, UK, (now M/s Johnson & Johnson Pvt Ltd)," Choubey said in his reply.

He said the government had set up a panel to examine issues relating to the faulty hip implants. The committee, after a detailed examination of the issue, submitted its report to the government, which accepted the recommendations with some modifications.

Based on the accepted recommendations, the government constituted a central expert committee under the chairmanship of Sports Injury Centre Director RK Arya inter-alia to determine the quantum of compensation, Choubey said.

The Health Ministry has also requested all the states/UTs to form state-level committees to examine the affected patients within their jurisdiction so that the process is less arduous for them.

"A formula for determining compensation for the affected patients has also been formulated and placed in public domain. The affected patients can approach either the central expert committee or state-level committee as per their convenience," Choubey said.

Responding to a question on whether the government was aware that the hip implants of the same manufacturer were recalled in the United States due to its faulty equipments and if so, the reasons it was allowed to market the product in India, Choubey said the product was recalled in the US in August 2010.

In India, the firm recalled it on August 24, 2010 and Central Drugs Standard Control Organisation (CDSCO) acknowledged their recall and no further import of the product was allowed, he said.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 12 2018 | 7:40 PM IST

Next Story